Cantor Fitzgerald reissued their buy rating on shares of NewLink Genetics Corporation (NASDAQ:NLNK) in a report issued on Thursday, November 2nd. Cantor Fitzgerald currently has a $26.00 target price on the biotechnology company’s stock.
“Path Forward in Melanoma. Indoximod is expected to enter a pivotal Phase III trial in combination with both Keytruda and Opdivo, with a planned enrollment of 600 patients. The trial design aims to compare PD-1 monotherapy to combination treatments, with co-primary endpoints of overall survival (OS) and progression free survival (PFS).”,” Cantor Fitzgerald’s analyst commented.
Other research analysts have also issued research reports about the stock. ValuEngine lowered shares of NewLink Genetics Corporation from a sell rating to a strong sell rating in a report on Tuesday, September 26th. Zacks Investment Research lowered shares of NewLink Genetics Corporation from a hold rating to a sell rating in a research note on Wednesday, July 12th. Robert W. Baird upgraded shares of NewLink Genetics Corporation from a neutral rating to an outperform rating and lifted their price objective for the company from $8.00 to $22.00 in a research note on Friday, September 8th. Stifel Nicolaus lifted their price objective on shares of NewLink Genetics Corporation from $14.00 to $29.00 and gave the company a buy rating in a research note on Monday, September 11th. Finally, Jefferies Group LLC reiterated a hold rating and set a $7.00 price objective on shares of NewLink Genetics Corporation in a research note on Friday, July 14th. One investment analyst has rated the stock with a sell rating, one has given a hold rating and six have assigned a buy rating to the company. The stock presently has a consensus rating of Buy and a consensus target price of $23.43.
NewLink Genetics Corporation (NLNK) opened at $8.36 on Thursday. NewLink Genetics Corporation has a 1-year low of $5.90 and a 1-year high of $25.17.
COPYRIGHT VIOLATION NOTICE: “NewLink Genetics Corporation (NLNK) Earns “Buy” Rating from Cantor Fitzgerald” was first published by Week Herald and is owned by of Week Herald. If you are reading this news story on another domain, it was copied illegally and republished in violation of US and international copyright law. The legal version of this news story can be accessed at https://weekherald.com/2017/11/15/newlink-genetics-corporations-nlnk-buy-rating-reiterated-at-cantor-fitzgerald.html.
In other news, major shareholder Stine Seed Farm, Inc. purchased 780,487 shares of NewLink Genetics Corporation stock in a transaction dated Friday, October 6th. The stock was bought at an average price of $10.25 per share, with a total value of $7,999,991.75. Following the completion of the acquisition, the insider now owns 7,857,732 shares in the company, valued at approximately $80,541,753. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Insiders own 13.70% of the company’s stock.
Hedge funds and other institutional investors have recently modified their holdings of the stock. Zurcher Kantonalbank Zurich Cantonalbank raised its stake in shares of NewLink Genetics Corporation by 1,823.0% during the third quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 10,269 shares of the biotechnology company’s stock valued at $105,000 after purchasing an additional 9,735 shares in the last quarter. Oppenheimer & Co. Inc. bought a new stake in shares of NewLink Genetics Corporation during the third quarter valued at about $114,000. UBS Asset Management Americas Inc. bought a new stake in shares of NewLink Genetics Corporation during the first quarter valued at about $297,000. Gotham Asset Management LLC bought a new stake in shares of NewLink Genetics Corporation during the first quarter valued at about $313,000. Finally, American International Group Inc. raised its stake in shares of NewLink Genetics Corporation by 7.1% during the first quarter. American International Group Inc. now owns 13,321 shares of the biotechnology company’s stock valued at $321,000 after purchasing an additional 880 shares in the last quarter. Institutional investors and hedge funds own 45.31% of the company’s stock.
NewLink Genetics Corporation Company Profile
NewLink Genetics Corporation is a clinical-stage immuno-oncology company focused on discovering, developing and commercializing immunotherapeutic products for the treatment of cancer. The Company’s portfolio includes biologic and small-molecule immunotherapy product candidates for a range of oncology indications.
Receive News & Ratings for NewLink Genetics Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NewLink Genetics Corporation and related companies with MarketBeat.com's FREE daily email newsletter.